Immune-related adverse events predict the therapeutic efficacy of anti-PD-1 antibodies in cancer patients.
暂无分享,去创建一个
A. Alfranca | R. Colomer | A. Ramos-Leví | M. Adrados | P. Gullón | R. Arranz | N. Romero-Laorden | R. Mondéjar | J. Rogado | A. Ballesteros | V. Pacheco-Barcia | J. Aspa | O. Donnay | J. Sanchez-Torres | R. Colomer | A. Lorenzo | P. Costas | A. Ramos-Levi